Accelerating Drug Discovery for Frontotemporal Dementias

he Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support drug discovery for FTD and related dementias through this Request for Proposals (RFP).

Priority areas for this program include:

  • Neuroprotection
  • Inflammation
  • Proteostasis
  • Mitochondria & metabolic function
  • Vascular function
  • Epigenetics
  • APOE
  • Synaptic activity and neurotransmitters
  • Other aging target (e.g. senescent cells)

ADDF/AFTD will provide grants for one-year duration ($150,000-$600,000 based on stage and scope of research.) with the possibility of follow-on funding. Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program-related investment.

Deadline for submitting proposals: LoI 12th July 2019.

Torna in alto